NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹20.33
- Market cap
- ₹112.2 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 46.3×Sector 46.1×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Other business update announcements
All →Hero MotoCorp Business Update
Hero MotoCorp updated its code of practices for fair disclosure of unpublished price-sensitive information, effective 28 October 2026. The revised code governs disclosure, spokespersons and analyst interactions.
Cybele Industries Business Update
Cybele Industries disclosed joint venture discussions with a third party, still at an initial stage. No agreement has been executed and no value is stated.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Vascon Engineers Business Update
Vascon Engineers awarded Neobridge Realty LLP a Rs.72 Crore shell and core work contract over 25 months. The contract is excluding GST and is described as ordinary course of business.
- Value
- ₹72.00 Cr
- Execution
- 25 months
Meesho Business Update
Meesho's Q2 FY27 shareholders' letter reports NMV up 23% YoY to ₹12,911 crore. Festive timing moved the Mega Blockbuster Sale into Q3.
Dhruv Consultancy Services Business Update
Dhruv Consultancy received an empanelment letter of intent for DPR work for Chhattisgarh government departments, valid for 36 months. No contract value or allotted work was disclosed.
- Execution
- 36 months